Specipig -Helping to develop more efficient and safe biomedical devices

In the recent 5 years, Specipig has participated in 15 brokerage events. As a result, thecompany has met more than 100 potential partners in the research and development of more efficient and safe biomedical devices.

Specipig

Specipig is a Catalan pioneer breeding and biomedical research center focused on the pig model. As CRO (Contract Research Organization) it supports the pharmaceutical, biotechnology, tissue regeneration and medical device industries especially where an in-vivo test and a large animal model is of interest. Specipig is specialisedin the swine model, a good animal model for clinical validation of medical and surgical devices. Due to its excellent quality and characteristics, the research is simpler and more targeted which reduces the number of attempts held. Specipig is GLP certified. In October 2016, the company joined the Meet in Italy for Life Sciences Brokerage Event(MIT4LS), where held a meeting with a startup from Italy. The Italian company was developing an implantable biomaterial and Specipig proved to be the perfect partner to test in pigs before the human implementation. The same year 2016, the CRO attended MEDICA Trade Fair, the leading international event in the Healthcare sector and joinedthe Healthcare Medica Brokerage Event, also organized by the EEN. Specipig was then introduced to a collaborative research project coordinated by a French medtech company. Its focus was to develop implants for the treatment of patients suffering from larynx malfunction. Since its inception the French company has worked on programs aiming at improving the biocompatibility of the implants and the quality of tissue reaction. In that frame, Specipig appeared once again as the perfect solution to test implants.The Catalan company started the trials on 2017: a prototype was implanted and subsequently a monitoring of the breathing and the swallowing of the pig was performed.

  • “The Enterprise Europe Network is an excellent tool to increase our contacts network and find new projects within Europe."

  • In the recent 5 years, Specipig has participated in 15 brokerage events. As a result, the company has met more than 100 potential partners in the research and development of more efficient and safe biomedical devices.